Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19
Comput Struct Biotechnol J. 2024 Jan 9;24:115-125. doi: 10.1016/j.csbj.2023.12.045. eCollection 2024 Dec.
ABSTRACT
BACKGROUND: Post-acute sequelae of COVID-19 (PASC) produce significant morbidity, prompting evaluation of interventions that might lower risk. Selective serotonin reuptake inhibitors (SSRIs) potentially could modulate risk of PASC via their central, hypothesized immunomodulatory, and/or antiplatelet properties although clinical trial data are lacking.